INCLUSION OF MODERATE-TO-SEVERE EZCEMA UNDER CHRONIC DISEASE MANAGEMENT PROGRAMME

NOTICE PAPER NO. 44

NOTICE OF QUESTION FOR WRITTEN ANSWER

FOR THE SITTING OF PARLIAMENT ON OR AFTER 25 SEPTEMBER 2025

Name and Constituency of Member of Parliament

Assoc Prof Jamus Jerome Lim

MP for Sengkang GRC

Question No. 232

To ask the Minister for Health whether the Ministry will consider including moderate-to-severe eczema under the Chronic Disease Management Programme.

Answer

1            Conditions under the Chronic Disease Management Programme (CDMP) are regularly reviewed by a Clinical Advisory Committee (CAC), comprising Family Physicians and specialists from the public and private sectors. In assessing the inclusion of conditions onto the CDMP, the CAC consults clinical experts in various healthcare settings, and considers factors such as disease burden, potential benefits of early interventions to patient outcomes, the cumulative cost to the patient from long-term treatment, and the availability of evidence-based clinical guidelines for appropriate care of the condition.

2            Eczema will be assessed for inclusion into the CDMP.

3            Even though eczema is currently not on the CDMP, patients can already access subsidised treatments for eczema today. Eligible patients may receive subsidies of up to 75% at polyclinics and Specialist Outpatient Clinics for their eczema treatment and medications. Patients aged 60 years and above can also tap on Flexi-MediSave to pay for eczema treatments and medications, up to the prevailing withdrawal limit.